Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment.
about
Bioinformatic analysis of HIV-1 entry and pathogenesis.Functional properties of the HIV-1 long terminal repeat containing single-nucleotide polymorphisms in Sp site III and CCAAT/enhancer binding protein site I.Evidence of Divergent Amino Acid Usage in Comparative Analyses of R5- and X4-Associated HIV-1 Vpr SequencesGenetic variation and HIV-associated neurologic disease.Cocaine alters cytokine profiles in HIV-1-infected African American individuals in the DrexelMed HIV/AIDS genetic analysis cohortDefining differential genetic signatures in CXCR4- and the CCR5-utilizing HIV-1 co-linear sequences.HIV-1 transcriptional regulation in the central nervous system and implications for HIV cure researchHIV Excision Utilizing CRISPR/Cas9 Technology: Attacking the Proviral Quasispecies in Reservoirs to Achieve a CureHIV-1 Promoter Single Nucleotide Polymorphisms Are Associated with Clinical Disease SeverityHIV-1 Genetic Variation Resulting in the Development of New Quasispecies Continues to Be Encountered in the Peripheral Blood of Well-Suppressed PatientsImpact of Tat Genetic Variation on HIV-1 DiseaseUtilization of HIV-1 envelope V3 to identify X4- and R5-specific Tat and LTR sequence signaturesDeployment of the human immunodeficiency virus type 1 protein arsenal: combating the host to enhance viral transcription and providing targets for therapeutic developmentEpigenetics, drugs of abuse, and the retroviral promoter.Specific amino acids in HIV-1 Vpr are significantly associated with differences in patient neurocognitive status.Impact of viral activators and epigenetic regulators on HIV-1 LTRs containing naturally occurring single nucleotide polymorphisms.
P2860
Q27693321-AAADE8FE-E710-4728-A55E-043089EC5E43Q33716931-B2159F24-9B8D-44CE-8865-EB01FA562A7AQ33768060-138E4EF3-7D36-49F3-83B8-708C3261D70AQ33819189-15EEE442-B0F1-4D8D-B102-3638D12C7A80Q34097854-FD6AF992-93B3-467A-A747-0C8F5EAB1188Q34267043-7ADEB75C-7BF1-43BE-B8FA-35F468A29F46Q35009720-C588F660-1D0F-4E94-97A0-F449D83AFCFDQ35447267-A0924255-0BB2-4D88-94EA-0439692488FFQ35995791-715DD2AD-CE8C-4D10-AFA0-B03346EF6695Q36022372-3EEDB118-8963-4535-901B-1C364A990636Q36148507-11FD9309-1BD8-4D16-B089-24B28ACCA773Q36867198-9674CEC4-7752-4A4D-8504-8CDE226434ADQ37127522-493438CE-FFDA-4216-97D1-C9D9B947B04FQ37425468-4AC0930F-EDC4-42D2-8870-D9C4B3E666A8Q40618199-CAC8094D-B4DD-43FC-BC74-09D36F0D6C22Q41517609-1DB2022D-75F0-4952-8CAA-EF407F4D09D7
P2860
Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Development of co-selected sin ...... ted neurocognitive impairment.
@ast
Development of co-selected sin ...... ted neurocognitive impairment.
@en
Development of co-selected sin ...... ted neurocognitive impairment.
@nl
type
label
Development of co-selected sin ...... ted neurocognitive impairment.
@ast
Development of co-selected sin ...... ted neurocognitive impairment.
@en
Development of co-selected sin ...... ted neurocognitive impairment.
@nl
prefLabel
Development of co-selected sin ...... ted neurocognitive impairment.
@ast
Development of co-selected sin ...... ted neurocognitive impairment.
@en
Development of co-selected sin ...... ted neurocognitive impairment.
@nl
P2093
P2860
P1476
Development of co-selected sin ...... ted neurocognitive impairment.
@en
P2093
Adam Wojno
Benjamas Aiamkitsumrit
Brandon Blakey
Brian Moldover
Brian Wigdahl
David Downie
Dennis Kolson
Evelyn Kilareski
Jeffrey M Jacobson
P2860
P2888
P304
P356
10.1007/S13365-010-0014-1
P577
2011-01-12T00:00:00Z